相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer
Hanna Sallinen et al.
BMC CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
Pierre-Emmanuel Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
I. Vergote et al.
EUROPEAN JOURNAL OF CANCER (2014)
Novel therapies, including enzastaurin, in the treatment of ovarian cancer
Ignace Vergote
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
Ignace Vergote et al.
GYNECOLOGIC ONCOLOGY (2014)
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-Mechanistics, review of phase III randomized clinical trials, and regulatory implications
Ramez N. Eskander et al.
GYNECOLOGIC ONCOLOGY (2014)
Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2014)
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
Toshihiko Doi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
MJ Brauer et al.
CLINICAL CANCER RESEARCH (2013)
Incidence and management of edema associated with trebananib (AMG 386)
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions
Stacey D. Finley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
A. Lortholary et al.
ANNALS OF ONCOLOGY (2012)
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer
Deanna Teoh et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer
Anil K. Sood et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer
Ewan J. D. Robson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2010)
Bevacizumab toxicities and their management in ovarian cancer
Leslie M. Randall et al.
GYNECOLOGIC ONCOLOGY (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody
Angela Coxon et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
Rebecca L. Stone et al.
LANCET ONCOLOGY (2010)
Weekly paclitaxel in the treatment of recurrent ovarian cancer
Richard D. Baird et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting the ANGPT-TIE2 pathway in malignancy
Hanhua Huang et al.
NATURE REVIEWS CANCER (2010)
Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
Beverly L. Falcon et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
John M. L. Ebos et al.
CLINICAL CANCER RESEARCH (2009)
Trials With Impact on Clinical Management First Line
Michael A. Bookman
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Yongping Crawford et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiopoietin: A TIE(d) balance in tumor angiogenesis
Winston S. N. Shim et al.
MOLECULAR CANCER RESEARCH (2007)
Is angiogenesis an organizing principle in biology and medicine?
Judah Folkman
JOURNAL OF PEDIATRIC SURGERY (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2006)
Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling
L Eklund et al.
EXPERIMENTAL CELL RESEARCH (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma
HZ Chen et al.
GYNECOLOGIC ONCOLOGY (2004)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
分享论文
